The impact of direct‐acting antiviral agents on liver and kidney transplant costs and outcomes

Direct‐acting antiviral medications (DAAs) have revolutionized care for hepatitis C positive (HCV+) liver (LT) and kidney (KT) transplant recipients. Scientific Registry of Transplant Recipients registry data were integrated with national pharmaceutical claims (2007‐2016) to identify HCV treatments...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2018-10, Vol.18 (10), p.2473-2482
Hauptverfasser:	Axelrod, D. A., Schnitzler, M. A., Alhamad, T., Gordon, F., Bloom, R. D., Hess, G. P., Xiao, H., Nazzal, M., Segev, D. L., Dharnidharka, V. R., Naik, A. S., Lam, N. N., Ouseph, R., Kasiske, B. L., Durand, C. M., Lentine, K. L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs clinical research/practice Death economics Female Follow-Up Studies Graft rejection Graft Survival Grafts Health risk assessment health services and outcomes research Hepacivirus - drug effects Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C - virology Humans infection and infectious agents – viral: hepatitis C kidney (allograft) function/dysfunction Kidney transplantation Kidney Transplantation - economics Kidney Transplantation - mortality kidney transplantation/nephrology Kidney transplants liver allograft function/dysfunction Liver transplantation Liver Transplantation - economics Liver Transplantation - mortality liver transplantation/hepatology Liver transplants Male Middle Aged patient survival Prognosis Registries Retrospective Studies Risk Factors Survival Rate Tissue Donors - supply & distribution Transplant Recipients Waiting Lists - mortality Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!